Janux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs

Reuters

07-25

Janux <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs

Janux Therapeutics Inc. recently held an R&D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer (mCRPC), and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2554735671"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554735671\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2554735671?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-25 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554735671","market":"nz","top_or_hot":-1,"title":"Janux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Janux <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils R&amp;D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Janux Therapeutics Inc. recently held an R&amp;D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&amp;I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer (mCRPC), and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Janux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-25 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Janux <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils R&amp;D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Janux Therapeutics Inc. recently held an R&amp;D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&amp;I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer (mCRPC), and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL3kL1Hg:1","article_id":"2554735671","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554735671","pubTimestamp":1753393135,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Janux Therapeutics Inc. recently held an R&D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer , and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative arti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","JANX":"Janux Therapeutics, Inc."},"translate_title":"Janux Therapeutics推出研发演示，重点介绍癌症和自身免疫性疾病项目的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JANX":0.9},"content_text":"Janux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs\n    \n\n        Janux Therapeutics Inc. recently held an R&D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer (mCRPC), and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}